AGREEMENTStatement on Schedule 13g • February 25th, 2014 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • July 21st, 2014 • Strategic Value Partners, LLC • Deep sea foreign transportation of freight
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Genco Shipping & Trading Limited is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 12th, 2015 • Baker Bros. Advisors Lp • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Invitae Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2020 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Shares of InflaRx N.V. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • November 14th, 2024 • Baker Bros. Advisors Lp • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Celcuity Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 16th, 2021 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Ordinary Shares of Opthea Limited is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2014 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of TG Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • January 8th, 2018 • Strategic Value Partners, LLC • Electric services
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Class A Common Stock of TerraForm Power, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 13th, 2019 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Principia Biopharma Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • January 12th, 2015 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Bellicum Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 13th, 2019 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Krystal Biotech, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2022 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Nurix Therapeutics, Inc.is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 12th, 2024 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Ordinary Shares of Bicycle Therapeutics plc is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 16th, 2021 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Ordinary Shares of Adaptimmune Therapeutics plc is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2014 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Stemline Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • August 12th, 2013 • Baker Felix • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Diadexus, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2022 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G (including additional amendments thereto) relating to the Ordinary Shares of Achilles Therapeutics plc is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • October 10th, 2014 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of XenoPort, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • January 10th, 2024 • Baker Bros. Advisors Lp • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Sera Prognostics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • July 21st, 2014 • Strategic Value Partners, LLC • Deep sea foreign transportation of freight
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Genco Shipping & Trading Limited is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • August 12th, 2013 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Vanda Pharmaceuticals Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • August 12th, 2013 • Baker Felix • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Derma Sciences, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 13th, 2018 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Ritter Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • January 6th, 2014 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Ordinary Shares of Celsus Therapeutics PLC is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2024 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Sagimet Biosciences Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2014 • Baker Bros. Advisors Lp • Services-commercial physical & biological research
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Anacor Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • November 14th, 2024 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Edgewise Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 16th, 2021 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Altimmune, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • November 14th, 2024 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Stoke Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2023 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of HOOKIPA Pharma Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 13th, 2018 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Aeglea BioTherapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • August 12th, 2013 • Baker Felix • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of ViroPharma Incorporated is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • April 10th, 2018 • Baker Bros. Advisors Lp • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Invitae Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 13th, 2018 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of CymaBay Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTStatement on Schedule 13g • February 14th, 2024 • Baker Bros. Advisors Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Mirati Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
